A recent study found that discontinuation of immunosuppressive therapies during COVID-19 in patients with ulcerative colitis (UC) was independently associated with long-term effects of COVID-19 (odds ratio = 1.50 [95% CI, 1.07-10.22], P = .01). Patients with Crohn's disease (CD) who were hospitalized for acute COVID-19 were nearly three times more likely to report persistent symptoms 12 weeks after acute infection.
Among patients with IBD, fatigue was the most common long COVID symptom (37% of patients with CD, 36% of patients with UC). Anosmia and ageusia were also common long COVID symptoms, with anosmia reported by 29% and 27% of patients with CD and UC, respectively, and ageusia reported by 28% and 19% of patients with CD and UC, respectively.
Along with IBD disease activity, older age, and presence of comorbidities, smoking was not associated with a significantly elevated risk for long COVID.
Learn more about IBD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Rapid Review Quiz: Long COVID - Medscape - Mar 22, 2022.